Supplementary Figures 1-9, Table 1 from hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy
Eran Elyakim(Regulus Therapeutics (United States)), Noga Yerushalmi(Regulus Therapeutics (United States)), Eve Montia(Regulus Therapeutics (United States)), Avital Dov(Tel Aviv University), Einat Sitbon(Regulus Therapeutics (United States)), Eric G. Marcusson(Ionis Pharmaceuticals (United States)), Ayelet Chajut(Rosetta Genomics (Israel)), Sarit Tabak(Rosetta Genomics (Israel)), Alexander Faerman(Regulus Therapeutics (United States)), Liron Belanis(Regulus Therapeutics (United States)), Dalia Cohen(Regulus Therapeutics (United States)), C. Frank Bennett
Cited by 0
Related Papers
MicroRNAs accurately identify cancer tissue origin
|Nature Biotechnology|2008|987
Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma
|Journal of Clinical Oncology|2009|410
Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects
|Journal of Biological Chemistry|1999|393
Design of a genome-wide siRNA library using an artificial neural network
|Nature Biotechnology|2005|386
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
|Journal of Clinical Investigation|2007|377